The “Triple-G” Weight Loss Drug That Could Outperform Ozempic
Topic: Eli Lilly’s retatrutide Phase 3 success — plans FDA filing for “Triple-G” obesity peptide (July 23, 2026) You’ve heard of Ozempic (semaglutide) and Mounjaro (tirzepatide) — the injectable weight loss drugs that have dominated headlines for the past two…
